BK-virus nephropathy

This expanded access program lets doctors in Texas give banked, partially matched virus-specific T cells to children under 18 who have persistent or recurring EBV, CMV, adenovirus, or BK virus infections after an allogeneic stem cell transplant or CAR T therapy. The cells come fr…

This study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether specially grown immune cells from an unrelated donor can safely treat viral infections in people with weakened immune systems, such as after a stem cell transplant. About 750 participants will receive these cells and be monitored for side effects like inf…

This early-phase trial is testing whether immune cells called R-MVST cells, grown quickly from a healthy donor, can safely fight off stubborn viral infections (EBV, CMV, adenovirus, or BK virus) in children and young adults with weakened immune systems. Participants have not resp…

This study tests a new cell therapy called LB-DTK-MV in children aged 1-25 who have stubborn viral infections (CMV, EBV, or BKV) after a stem cell transplant. The therapy uses specially grown immune cells from a donor to attack the viruses. Participants receive two infusions two …

This early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain c…

This study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …

This early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…

This early-stage trial tests whether specially grown immune cells from a donor can safely help transplant patients fight off viral infections that standard treatments can't control. The cells target Epstein-Barr virus, cytomegalovirus, adenovirus, and BK virus. Up to 36 adults wh…

This study tests whether reducing anti-rejection drugs, with or without an extra treatment called IVIG, can better control BK virus in kidney transplant patients. BK virus can damage the new kidney and lead to transplant failure. About 280 adults and children who have a kidney or…

This study tests whether specially grown immune cells (called cytotoxic T lymphocytes) can safely lower BK virus levels in 20 transplant patients with weakened immune systems. Participants have had a stem cell or kidney transplant and show signs of BK virus infection. The goal is…

This study tests whether specially grown immune cells (BK-specific cytotoxic T-cells) from a related donor can safely lower BK virus levels in children, teens, and young adults. Participants have BK infections that did not get better with standard treatment, often after a stem ce…

This registry study is collecting blood and urine samples from 60 kidney transplant recipients who have BK virus infection. Researchers want to understand how the immune system responds to the virus and how immunosuppressive drugs affect that response. The goal is to find better …

This study looks at 100 kidney transplant patients to understand where the BK virus comes from and why some people get sicker than others. Researchers will compare the virus in patients and their donors, and check how the immune system responds. The goal is to find better ways to…